Loading
A phase 3 trial of Mitoxantrone and Tucidinostat (chidamide) in peripheral T-cell lymphomas, run by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., active and no longer recruiting.
Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL is a phase 3 interventional study registered as NCT04668690 by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., with 193 participants enrolled, started 2021-04-13 and due to reach its primary completion in 2027-12-30. Interventions recorded: Mitoxantrone Hydrochloride Liposome Injection and Chidamide.
Shares Tucidinostat (chidamide), Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Tucidinostat (chidamide), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares CSPC Pharmaceutical Group, Cytotoxic chemotherapy and the tag pipeline.
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Cytotoxic chemotherapy and the tag pipeline.
Shares CSPC Pharmaceutical Group, Cytotoxic chemotherapy and the tag pipeline.
Shares Topoisomerase-I inhibitors (and ADC payloads), Cytotoxic chemotherapy and the tag pipeline.
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Cytotoxic chemotherapy and the tag pipeline.
Shares CSPC Pharmaceutical Group, Cytotoxic chemotherapy and the tag pipeline.